SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL. Rituxan is administered with two other chemotherapy drugs,...
ScienceDaily (Jan. 25, 2010) — Immune cells known as myeloid-derived suppressor cells (MDSCs) keep other immune cells in check. They have been found to accumulate in individuals with cancer, where they are thought to contribute to tumor development.
François Ghiringhelli and colleagues, at INSERM U866, Dijon, France, have now identified a molecular pathway that enhances the immunosuppressive functions of tumor-associated mouse and human MDSCs.
Medical News Today
Article Date: 23 Oct 2009 - 3:00 PDT
Cancer patients don't have time to waste, yet many must endure a tedious process of elimination as physicians try several different treatments until identifying the one that is most effective against their particular type of tumor. Now researchers at the University of Virginia Health System have developed a breakthrough method that could one day eliminate this trial and error approach to treating many cancers.
* Positive top-line results from cancer drug phase II study
* Says it shows potential for treatment of front line NHL
* Positive results just nine days after drug disappointed
By Teis Jensen
COPENHAGEN, Aug 26 (Reuters) - The Danish biotech company Genmab said on Wednesday that it got positive top-line results from a phase II study of its Arzerra cancer drug, which is being co-developed with GlaxoSmithKline....
AJHO: The American Journal of Hematology/Oncology
August 18, 2009
● RESEARCHERS OF THE CHILDREN'S ONCOLOGY GROUP HAVE DEVELOPED a new chemotherapy regimen known as ABVE-PC to treat patients with pediatric Hodgkin lymphoma (HL). Led by Cindy Schwartz, MD, director of pediatric hematology/ oncology at Hasbro Children's Hospital in Providence, Rhode Island, the group combined six different drugs into a dose-dense regimen that achieves rapid early response and limits...
